ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single - agent activity in a Phase I study of patients with CML with failure of prior TKI therapy

Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330, Alimena, Giuliana, DeAngelo, Daniel J., Goh, Yeow-Tee, Heinrich, Michael C., Hochhaus, Andreas, Hughes, Timothy P., Mahon, Francois-Xavier, Mauro, Michael J., Minami, Hironobu, Nguyen, Marie Huong, Rea, Delphine, Steegmann, Juan Luis, Chatterjee, Arkendu, Iyer, Varsha, Martinez, Noelia, Vanasse, Gary J. and Dong-Wook, Kim 2015. ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single - agent activity in a Phase I study of patients with CML with failure of prior TKI therapy. Blood 126 (23) , 138.

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	American Society of Hematology
ISSN:	0006-4971
Last Modified:	02 Nov 2022 09:54
URI:	https://orca.cardiff.ac.uk/id/eprint/96763

Actions (repository staff only)

Edit Item